Submitted:
25 June 2025
Posted:
26 June 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
- Study design
- Cardiac evaluation
- Surgical details and follow-up protocol
- Definitions
- Outcomes
- Statistical Analysis
3. Results
3.1. Clinical Profile, Anatomic Characteristics and Surgical Details
3.2. Bypass Related Outcomes
| Variable | level | Group B | Group A | p-value |
|---|---|---|---|---|
| Bypass-related complications within 30 days n (%) |
No | 91 (68.4) | 16 (64.0) | 0.841 |
| Yes | 42 (31.6) | 9 (36.0) | ||
| Patency, n (%) | No |
41 (31.5) | 9 (36.0) | 0.839 |
| Yes | 89 (68.5) | 16 (64.0) | ||
| Restenosis, n (%) | No | 87 (97.8) | 16 (100.0) | 1.000 |
| Yes | 2 (2.2) | 0 (0.0) | ||
| First complication after 30 days n (%) | No | 77 (57.9) | 12 (48.0) | 0.487 |
| Yes | 56 (42.1) | 13 (52.0) | ||
| Second complication after 30 days n (%) | No | 112 (84.2) | 21 (84.0) | 1.000 |
| Yes | 21 (15.8) | 4 (16.0) | ||
| Third complication after 30 days n (%) | No | 124 (93.2) | 21 (84.0) | 0.252 |
| Yes | 9 (6.8) | 4 (16.0) | ||
| Fourth complication after 30 days n (%) | No | 132 (99.2) | 22 (88.0) | 0.010 |
| Yes | 1 (0.8) | 3 (12.0) | ||
| Mean number of complication after 30 days [SD] |
0.65 [0.89] | 0.96 (1.34) | 0.429 | |
| Major amputation (%) | No | 111 (83.5) | 20 (80.0) | 0.895 |
| Yes | 22 (16.5) | 5 (20.0) | ||
| Time between intervention and major amputation in days (median, [IQR]) | 100.00 [64.50, 283.25] | 449.00 [432.00, 1144.00] | 0.016 |
| Univariate logistic model “Major Amputation” | |||
|---|---|---|---|
| Predictors | Odds Ratio | OR 95%CI | pvalue |
| AVA | 0.76 | (0.27, 2.49) | 0.638 |
| Age | 1.02 | (0.97, 1.07) | 0.420 |
| Complications within 30 days [yes vs no] | 5.83 | (2.36, 14.57) | <0.001 |
| Functional status [Impaired, but able vs not impaired] | 2.42 | (0.87, 25.67) | 0.109 |
| [Needs some assistance vs not impaired] | 10.37 | (1.72, 45.82) | 0.016 |
| [Requiring total assistance vs not impaired] | 6.67 | (1.91, 79.39) | 0.010 |
| Graft related complications [yes vsno] | 2.74 | (1.17, 6.45) | 0.020 |
| Bypass lenght | 7.72 | (1.53, 140.68) | 0.049 |
| Cardiac status [recent MI vs asymptomatic] | 2.65 | (1.14, 6.26) | 0.024 |
3.3. Clinical Outcomes
| Variable | level | Group B | Group A | p-value |
|---|---|---|---|---|
| Major Adverse Event (MAE) (%) | No | 79 (59.4) | 13 (52.0) | 0.142 |
| Cardiovascular event (MI/stroke/Sudden Cardiac death) | 33 (24.8) | 4 (16.0) | ||
| Death for other causes or unknown | 21 (15.8) | 8 (32.0) | ||
| Death, n (%) | No | 79 (59.4) | 13 (52.0) | 0.640 |
| Yes | 33 (24.8) | 12 (48.0) | ||
| Cardiovascular death, n (%) | No | 100 (75.2) | 21 (84.0) | 0.486 |
| Yes | 33 (24.8) | 4 (16.0) | ||
| Times between intervention and any MAE in days (median [IQR]) | 936 [238, 1478] | 792.50 [159.25, 1431.50] | 0.673 | |
| Time between intervention and death in days (mean; median[IQR]) | 961; 744.50 [244.50, 1475.25] | 893; 559 [165.25, 1431.50] | 0.630 | |
| Time between intervention and cardiovascular death in days (mean; median [IQR]) | 822; 341 [150, 1467] | 358; 181 [86.75, 452.25] | 0.221 | |
| Postoperative functional status, n (%) | No impairment | 58 (43.9) | 7 (29.2) | 0.157 |
| Impaired, but able to carry out ADL without assistance | 20 (15.2) | 7 (29.2) | ||
| Needs some assistance to carry out ADL or ambulatory assistance | 23 (17.4) | 2 (8.3) | ||
| Requiring total assistance for ADL or nonambulatory | 31 (23.5) | 8 (33.3) |
| Univariate logistic model for variation of functional status | |||
|---|---|---|---|
| Predictors | Odds Ratio | OR 95%CI | pvalue |
| AVA | 0.45 | (0.16, 1.16) | 0.111 |
| Age | 1.08 | (1.04, 1.13) | <0.001 |
| Complications within 30 days [yes vs no] | 3.52 | (1.43, 10.04) | 0.010 |
| Functional status [Impaired, but able vs not impaired] | 3.02 | (1.28, 7.49) | 0.013 |
| [Needs some assistance vs not impaired] | 10.62 | (6.09, 51.17) | <0.001 |
| [Requiring total assistance vs not impaired] | 40.72 | (6.98, 782.41) | <0.001 |
| Graft related complications [yes vsno] | 1.82 | (0.91, 3.77) | 0.095 |
| Bypass lenght | 2.52 | (1.13, 5.82) | 0.026 |
| Cardiac status [recent MI vs asymptomatic] | 2.12 | (1.07, 4.30) | 0.033 |
| Rutherford scale | 2.24 | (1.38, 3.77) | 0.014 |
3.4. Figures, Tables and Schemes


4. Discussion
- Limitations
5. Conclusions
Funding
Author contributions
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013; 382:1329-40. [CrossRef]
- Manning WJ (October 2013). "Asymptomatic aortic stenosis in the elderly: a clinical review". JAMA. 310 (14): 1490-7.
- Stewart BF, Siscovick D, Lind BK, et al. (March 1997). "Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study." Journal of the American College of Cardiology. 29 (3): 630-4. [CrossRef]
- Holmes DR Jr, Brennan JM, Rumsfeld JS, Dai D, O’Brien SM, Vemulapalli S, Edwards FH, Carroll J, Shahian D, Grover F, Tuzcu EM, Peterson ED, Brindis RG, Mack MJ; STS/ACC TVT Registry. Clinical outcomes at 1 year following transcatheter aortic valve replacement. JAMA. 2015 Mar 10;313(10):1019-28. [CrossRef]
- Malyar NM, Kaier K, Freisinger E, Lüders F, Kaleschke G, Baumgartner H, Frankenstein L, Reinecke H, Reinöhl J. Prevalence and impact of critical limb ischaemia on in-hospital outcome in transcatheter aortic valve implantation in Germany. EuroIntervention. 2017 Dec 20;13(11):1281-1287. [CrossRef]
- Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, Mills JL, Ricco JB, Suresh KR, Murad MH; GVG Writing Group. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019 Jun;69(6S):3S-125S.e40. Epub 2019 May 28. Erratum in: J Vasc Surg. 2019 Aug;70(2):662. [CrossRef]
- Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, Jüni P, Pierard L, Prendergast BD, Sádaba JR, Tribouilloy C, Wojakowski W; ESC/EACTS Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Rev Esp Cardiol (Engl Ed). 2022 Jun;75(6):524. [CrossRef]
- Stoner MC, Calligaro KD, Chaer RA, Dietzek AM, Farber A, Guzman RJ, Hamdan AD, Landry GJ, Yamaguchi DJ, on behalf of the Society for Vascular Surgery. Reporting standards of the Society for Vascular Surgery for endovascular treatment of chronic lower extremity peripheral artery disease. J Vasc Surg 2016; 64: 1-21.
- Ueshima D, Barioli A, Nai Fovino L, D’Amico G, Fabris T, Brener SJ, Tarantini G. The impact of pre-existing peripheral artery disease on transcatheter aortic valve implantation outcomes: A systematic review and meta-analysis. Catheter Cardiovasc Interv. 2020 Apr 1;95(5):993-1000. [CrossRef]
- Shah KB, Elzeneini M, Neal D, Kamisetty S, Winchester D, Shah SK. Chronic Limb-Threatening Ischemia Is Associated with Higher Mortality and Limb Revascularization After Transcatheter Aortic Valve Replacement. Am J Cardiol. 2023 Nov 15; 207:202-205. [CrossRef]
- Romiti M, Albers M, Brochado-Neto FC, Durazzo AE, Pereira CA, De Luccia N. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg 2008; 47(5): 975-81. [CrossRef]
- Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary; a report of the American College of Cardiology/American Heart Association Task Force on Practice. Circulation. 2014;129(23): 2440-2492.
- Manning WJ (October 2013). "Asymptomatic aortic stenosis in the elderly: a clinical review". JAMA. 310 (14): 1490-7.
- Stewart BF, Siscovick D, Lind BK, et al. (March 1997). "Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study." Journal of the American College of Cardiology. 29 (3): 630-4. [CrossRef]
- Uhl C, Hock C, Ayx I, Zorger N, Steinbauer M, Töpel I. Tibial and peroneal bypasses in octogenarians and nonoctogenarians with critical limb ischemia. J Vasc Surg. 2016 Jun;63(6):1555-62. [CrossRef]
- Myers R, Mushtaq B, Taylor N, Rashid H, Pineda DM. Limb salvage in octogenarians with critical limb ischemia after lower extremity bypass surgery. J Vasc Surg. 2023 Jul;78(1):217-222.
- Morisaki K, Matsuda D, Guntani A, Aoyagi T, Kinoshita G, Yoshino S, Inoue K, Honma K, Yamaoka T, Mii S, Yoshizumi T. Treatment Outcomes in Octogenarians with Chronic Limb-Threatening Ischemia after Infrainguinal Bypass Surgery or Endovascular Therapy. Ann Vasc Surg. 2024 Sep;106:312-320. [CrossRef]
- Molnár AÁ, Nádasy GL, Dörnyei G, Patai BB, Delfavero J, Fülöp GÁ, Kirkpatrick AC, Ungvári Z, Merkely B. The aging venous system: from varicosities to vascular cognitive impairment. Geroscience. 2021 Dec;43(6):2761-2784. [CrossRef]
- Kvaslerud AB, Santic K, Hussain AI, Auensen A, Fiane A, Skulstad H, Aaberge L, Gullestad L, Broch K. Outcomes in asymptomatic, severe aortic stenosis. PLoS One. 2021 Apr 7;16(4):e0249610.
- Bellosta R, Piffaretti G, Bonardelli S, Castelli P, Chiesa R, Frigerio D, Lanza G, Pirrelli S, Rossi G, Trimarchi S; Lombardy Covid-19 Vascular Study Group. Regional Survey in Lombardy, Northern Italy, on Vascular Surgery Intervention Outcomes During The COVID-19 Pandemic. Eur J Vasc Endovasc Surg. 2021 Apr;61(4):688-697. [CrossRef]
- Taylor SM, Kalbaugh CA, Blackhurst DW, Cass AL, Trent EA, Langan EM 3rd, Youkey JR. Determinants of functional outcome after revascularization for critical limb ischemia: an analysis of 1000 consecutive vascular interventions. J Vasc Surg. 2006 Oct;44(4):747-55; discussion 755-6.
| Echo parameters | Sclerosis | Mild AS | Moderate AS | Severe AS |
|---|---|---|---|---|
| Peak velocity, m/s | <2.5 | 2.5 – 3 | 3-4 | >4 |
| Mean gradient, mmhg | Normal | <20 | 20-40 | 40 |
| AVA, cm2 | Normal | ≥ 1.5 | 1-1.5 | < 1 |
| Pre-operatory functional status | |
| 0 | No impairment |
| 1 | Impaired, but able to carry out ADL without assistance |
| 2 | Needs some assistance to carry out ADL or ambulatory assistance |
| 3 | Requiring total assistance for ADL or nonambulatory |
| Variable | level | Group B | Group A | p-value |
|---|---|---|---|---|
| N= 133 | N=25 | |||
| Sex (%) | Female | 39 (29.3) | 8 (32.0) | 0.976 |
| Male | 94 (70.7) | 17 (68.0) | ||
| Age (median, [IQR]) | 74.00 [65.00, 81.00] | 78.00 [76.00, 83.00] | 0.005 | |
| Vmax (median [IQR]) | 1.36 [1.17, 1.65] | 2.89 [2.60, 3.19] | <0.001 | |
| Mean Gp (median [IQR]) | 3.80 [2.90, 5.60] | 18.42 [13.16, 24.04] | <0.001 | |
| Weight, kg (median [IQR]) | 70.00 [58.00, 80.00] | 70.00 [55.00, 78.00] | 0.911 | |
| Height, m (median [IQR]) | 1.69 [1.62, 1.75] | 1.67 [1.64, 1.70] | 0.561 | |
| BMI (median [IQR]) | 24.69 [22.22, 26.67] | 24.80 [22.40, 27.66] | 0.971 | |
| Smoking habits (%) | No – past | 92 (69.2) | 19 (76.0) | 0.655 |
| yes | 41 (30.8) | 6 (24.0) | ||
| Diabetes (%) | No | 73 (54.9) | 11 (44.0) | 0.434 |
| yes | 60 (45.1) | 14 (56.0) | ||
| Hypertension (%) | No | 19 (14.3) | 2 (8.0) | 0.597 |
| Yes | 114 (85.7) | 23 (92.0) | ||
| Renal function impairment (%) | No impairment or mild | 116 (87.2) | 24 (96.0) | 0.355 |
| Severe or pre-terminal | 17 (12.8) | 1 (4.0) | ||
| Dislipidemia (%) | No | 34 (25.6) | 6 (24.0) | 1.000 |
| Yes | 99 (74.4) | 19 (76.0) | ||
| Cardiac status (%) | Asymptomatic or previous MI ( > 6 months) or silent | 86 (64.7) | 15 (60.0) | 0.827 |
| Recent MI (<6 mesi), arytmia, angina, reduction of EF | 47 (35.3) | 10 (40.0) | ||
| COPD (%) | No | 61 (45.9) | 11 (44.0) | 1.000 |
| Yes | 72 (54.1) | 14 (56.0) | ||
| Stroke (%) | No | 115 (86.5) | 23 (92.0) | 0.663 |
| Yes | 18 (13.5) | 2 (8.0) | ||
| Pre-operatory functional status (%) | No impairment | 39 (29.3) | 4 (16.0) | 0.479 |
| Impaired, but able to carry out ADL without assistance | 44 (33.1) | 8 (32.0) | ||
| Needs some assistance to carry out ADL or ambulatory assistance | 38 (28.6) | 10 (40.0) | ||
| Requiring total assistance for ADL or nonambulatory | 12 (9.0) | 3 (12.0) |
| Variable | level | Group B | Group A | p-value |
|---|---|---|---|---|
| Side n (%) | Right | 67 (50.4) | 8 (32.0) | 0.142 |
| Left | 66 (49.6) | 17 (68.0) | ||
| Rutherford Scale (%) | 3 - Severe claudication | 10 (7.5) | 2 (8.0) | 0.157 |
| 4 - Ischemic rest pain | 34 (25.6) | 4 (16.0) | ||
| 5 - Minor tissue lost | 83 (62.4) | 15 (60.0) | ||
| 6 - Major tissue lost | 6 (4.5) | 4 (16.0) | ||
| Level of rivascularization n (%) | Above the knee | 26 (19.5) | 5 (20.0) | 1.000 |
| Below the knee | 107 (80.5) | 20 (80.0) | ||
| Graft material, prosthesis n (%) | No | 47 (35.3) | 9 (36.0) | 1.000 |
| Yes | 86 (64.7) | 16 (64.0) | ||
| Graft material, great saphenous vein n (%) | No | 64 (48.1) | 10 (40.0) | 0.597 |
| Yes | 69 (51.9) | 15 (60.0) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).